NECLIFE
Nectar Lifescience Ltd
Each stock's 10,000-path forecast, rendered as light.
Nectar Lifescience Ltd (NECLIFE) Stock Analysis & Case Study
What the numbers say about NECLIFE, and the method behind each one.
Nectar Lifescience Ltd (NECLIFE) trades at ₹11,on the numbers it screens weak, a Downstox Snapshot Score of 31/100.
On the numbers, Nectar Lifescience Ltd (NECLIFE) screens weak, a Downstox Snapshot Score of 31/100, weighing premium at 30.0× earnings, ROE of -7.5%, a 46% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
NECLIFE fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How NECLIFE ranks against the 2,982 companies in our screener
- NECLIFE's market cap of 215 Cr ranks in the 26th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- NECLIFE's book value of ₹30 ranks in the 23rd percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- NECLIFE's promoter holding of 51.8% ranks in the 30th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- NECLIFE's 3-year profit (PAT) growth of 4.0% ranks in the 31st percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- NECLIFE's 3-year revenue growth of -89.0% ranks in the bottom 1% of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
We do not hold a debt-to-equity ratio figure for NECLIFE, as of 14 Aug 2026, so it is not ranked here.
Is NECLIFE overvalued? NECLIFE P/E vs peers
NECLIFE trades at 30.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
NECLIFE share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of NECLIFE history (-12%/yr drift, 58%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| NECLIFE 2027 | ₹5 | ₹10 | ₹22 | -6% |
| NECLIFE 2028 | ₹3 | ₹10 | ₹28 | -11% |
| NECLIFE 2029 | ₹3 | ₹9 | ₹33 | -16% |
| NECLIFE 2030 | ₹2 | ₹9 | ₹38 | -20% |
| NECLIFE 2031 | ₹2 | ₹8 | ₹43 | -25% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability NECLIFE goes up, or doubles?
The bull case for NECLIFE
- Low price-to-book of 0.37×, the market is paying little over the company's net assets.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹33.
The bear case & risks
- NECLIFE's P/E of 30.0x is lower than 41% of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- NECLIFE's Piotroski F-Score of 2/8 ranks in the 7th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026.
- High historical volatility (58%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹3.
NECLIFE volatility & expected range, how bumpy is the ride?
Over the last 9.8 years NECLIFE compounded at -12%/year with annualized volatility of 58%. That volatility implies a 1-year 80% range of ₹5-₹22, the honest backbone behind any single price target.
NECLIFE price forecast, the full 60-month probability fan
NECLIFE price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds NECLIFE hits common targets within the simulated horizon?
Full multi-horizon detail on the NECLIFE price target & forecast page.
NECLIFE Piotroski F-Score: 2/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. NECLIFE scores 2/8, weak on the financial-strength checks.
About Nectar Lifescience Ltd: sector, index & market-cap context
Nectar Lifescience Ltd (NECLIFE) is a small-cap NSE-listed company, with a market capitalisation of ₹215 Cr. See more stocks on our screener.
How the NECLIFE Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Nectar Lifescience Ltd's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
NECLIFE analysis, FAQs
Is Nectar Lifescience Ltd (NECLIFE) a good buy?
On the numbers, Nectar Lifescience Ltd (NECLIFE) screens weak, a Downstox Snapshot Score of 31/100, weighing premium at 30.0× earnings, ROE of -7.5%, a 46% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is NECLIFE overvalued or undervalued?
NECLIFE trades at 30.0× earnings, premium versus the ~22× long-run Nifty average.
What is the NECLIFE share price target for 2031?
NECLIFE's probability-weighted 2031 median target is ₹8, with an 80% range of ₹2-₹43 (10,000-path Monte-Carlo).
What is the probability NECLIFE doubles in 5 years?
The modelled probability of NECLIFE reaching ₹22 (2×) within 5 years is 22%.
What is the bull case for NECLIFE?
Low price-to-book of 0.37×, the market is paying little over the company's net assets.
What are the risks in NECLIFE?
NECLIFE's P/E of 30.0x is lower than 41% of the 2,982 NSE companies in our screener, as of 14 Aug 2026. NECLIFE's Piotroski F-Score of 2/8 ranks in the 7th percentile of the 2,982 NSE companies in our screener, as of 14 Aug 2026. High historical volatility (58%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
More on NECLIFE
For information and education only. Downstox is a data and analytics platform, not a SEBI-registered Research Analyst or Investment Adviser. Nothing here is investment advice or a recommendation to buy, sell or hold any security. Any scores, ranks, targets or scenarios are model estimates shown with their method, not forecasts or assured outcomes. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing.